Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

. Bevacizumab In Colorectal Cancer :

Bevacizumab, sold under the brand name Avastin, used to treat a several of types of cancers it was approved in the United States in February 2004, for use in metastatic colorectal cancer when used with standard chemotherapy treatment (as first-line treatment) and with 5-fluorouracil-based therapy for second-line metastatic colorectal cancer. Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer-related deaths in the US. During the recent years, the median survival of patients with metastatic colorectal cancer has improved dramatically. Gastroenterological interventions are frequently carried throughout the disease course, and familiarity with the various side effects of regimens which are commonly used in these patients is required.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Immunology & Microbiology

Get the App